193 related articles for article (PubMed ID: 1926908)
1. Pravastatin sodium, a new HMG-CoA reductase inhibitor.
Raasch RH
DICP; 1991 Apr; 25(4):388-94. PubMed ID: 1926908
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
Richter WO; Jacob BG; Schwandt P
Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
[TBL] [Abstract][Full Text] [Related]
6. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin.
Serajuddin AT; Ranadive SA; Mahoney EM
J Pharm Sci; 1991 Sep; 80(9):830-4. PubMed ID: 1800703
[TBL] [Abstract][Full Text] [Related]
7. A comparison of continuous combined hormone replacement therapy, HMG-CoA reductase inhibitor and combined treatment for the management of hypercholesterolemia in postmenopausal women.
Ozsener S; Sendag F; Koc T; Terek MC; Oztekin K; Bilgin O
J Obstet Gynaecol Res; 2001 Dec; 27(6):353-8. PubMed ID: 11794823
[TBL] [Abstract][Full Text] [Related]
8. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.
Tobert JA
Circulation; 1987 Sep; 76(3):534-8. PubMed ID: 3113763
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials.
Kong SX; Crawford SY; Gandhi SK; Seeger JD; Schumock GT; Lam NP; Stubbings J; Schoen MD
Clin Ther; 1997; 19(4):778-97. PubMed ID: 9377621
[TBL] [Abstract][Full Text] [Related]
10. Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin.
Lintott CJ; Scott RS; Sutherland WH; Bremer J
Aust N Z J Med; 1993 Aug; 23(4):381-6. PubMed ID: 8240151
[TBL] [Abstract][Full Text] [Related]
11. The effect of pravastatin on hepatic 3-hydroxy-3-methylglutaryl CoA reductase obtained from poloxamer 407-induced hyperlipidemic rats.
Johnston TP; Palmer WK
Pharmacotherapy; 1997; 17(2):342-7. PubMed ID: 9085326
[TBL] [Abstract][Full Text] [Related]
12. Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
Illingworth DR; Bacon S
Am J Cardiol; 1987 Oct; 60(12):33G-42G. PubMed ID: 3314447
[TBL] [Abstract][Full Text] [Related]
13. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
[TBL] [Abstract][Full Text] [Related]
14. Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study.
Stalenhoef AF; Lansberg PJ; Kroon AA; Kortmann B; De Haan AF; Stuyt PM; Kastelein JJ
J Intern Med; 1993 Jul; 234(1):77-82. PubMed ID: 8326293
[TBL] [Abstract][Full Text] [Related]
15. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro.
Kurakata S; Kada M; Shimada Y; Komai T; Nomoto K
Immunopharmacology; 1996 Aug; 34(1):51-61. PubMed ID: 8880225
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia.
Strauss WE; Lapsley D; Gaziano JM
Am Heart J; 1999 Mar; 137(3):458-62. PubMed ID: 10047626
[TBL] [Abstract][Full Text] [Related]
17. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
[TBL] [Abstract][Full Text] [Related]
18. A review of clinical trials comparing HMG-CoA reductase inhibitors.
Illingworth DR; Tobert JA
Clin Ther; 1994; 16(3):366-85; discussion 365. PubMed ID: 7923304
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Yee HS; Fong NT
Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
[TBL] [Abstract][Full Text] [Related]
20. Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model.
Ugawa T; Kakuta H; Moritani H; Shikama H
Br J Pharmacol; 2002 Mar; 135(6):1572-8. PubMed ID: 11906972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
